Northern Trust
SNDX icon

Northern Trust’s Syndax Pharmaceuticals SNDX Stock Holding History

Northern Trust’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$17.7M Buy
755,719
+26,798
+4% +$582K ﹤0.01% 1751
2025
Q4 		$15.3M Sell
728,921
-47,765
-6% -$833K ﹤0.01% 1840
2025
Q3 		$11.9M Buy
776,686
+6,235
+0.8% +$81.6K ﹤0.01% 2012
2025
Q2 		$7.22M Sell
770,451
-8,307
-1% -$91.4K ﹤0.01% 2250
2025
Q1 		$9.57M Sell
778,758
-13,992
-2% -$197K ﹤0.01% 2058
2024
Q4 		$10.5M Buy
792,750
+55,144
+7% +$944K ﹤0.01% 2094
2024
Q3 		$14.2M Buy
737,606
+40,877
+6% +$844K ﹤0.01% 1849
2024
Q2 		$14.3M Sell
696,729
-45,098
-6% -$944K ﹤0.01% 1778
2024
Q1 		$17.7M Buy
741,827
+63,722
+9% +$1.42M ﹤0.01% 1671
2023
Q4 		$14.7M Buy
678,105
+42,580
+7% +$655K ﹤0.01% 1837
2023
Q3 		$9.23M Sell
635,525
-28,942
-4% -$547K ﹤0.01% 2063
2023
Q2 		$13.9M Buy
664,467
+69,543
+12% +$1.45M ﹤0.01% 1829
2023
Q1 		$12.6M Buy
594,924
+45,833
+8% +$1.14M ﹤0.01% 1870
2022
Q4 		$14M Buy
549,091
+45,129
+9% +$1.05M ﹤0.01% 1785
2022
Q3 		$12.1M Buy
503,962
+16,049
+3% +$360K ﹤0.01% 1851
2022
Q2 		$9.39M Buy
487,913
+1,685
+0.3% +$28.1K ﹤0.01% 2077
2022
Q1 		$8.45M Buy
486,228
+32,552
+7% +$548K ﹤0.01% 2256
2021
Q4 		$9.93M Sell
453,676
-4,500
-1% -$83.1K ﹤0.01% 2231
2021
Q3 		$8.76M Sell
458,176
-761
-0.2% -$12.7K ﹤0.01% 2375
2021
Q2 		$7.88M Buy
458,937
+93,451
+26% +$1.71M ﹤0.01% 2537
2021
Q1 		$8.17M Buy
365,486
+17,712
+5% +$400K ﹤0.01% 2431
2020
Q4 		$7.74M Buy
347,774
+6,864
+2% +$142K ﹤0.01% 2416
2020
Q3 		$5.03M Sell
340,910
-13,839
-4% -$211K ﹤0.01% 2524
2020
Q2 		$5.26M Buy
354,749
+79,134
+29% +$1.21M ﹤0.01% 2488
2020
Q1 		$3.02M Buy
275,615
+34,066
+14% +$320K ﹤0.01% 2607
2019
Q4 		$2.12M Sell
241,549
-2,164
-0.9% -$15.9K ﹤0.01% 3103
2019
Q3 		$1.82M Buy
243,713
+55,631
+30% +$507K ﹤0.01% 3149
2019
Q2 		$1.75M Buy
188,082
+11,470
+6% +$83.6K ﹤0.01% 3145
2019
Q1 		$927K Buy
176,612
+1,120
+0.6% +$6.39K ﹤0.01% 3386
2018
Q4 		$781K Buy
175,492
+2,690
+2% +$14.7K ﹤0.01% 3440
2018
Q3 		$1.4M Sell
172,802
-2,075
-1% -$14.8K ﹤0.01% 3370
2018
Q2 		$1.23M Buy
174,877
+31,146
+22% +$306K ﹤0.01% 3406
2018
Q1 		$2.05M Sell
143,731
-10,270
-7% -$109K ﹤0.01% 3089
2017
Q4 		$1.35M Buy
154,001
+26,724
+21% +$264K ﹤0.01% 3312
2017
Q3 		$1.49M Sell
127,277
-2,919
-2% -$35.8K ﹤0.01% 3327
2017
Q2 		$1.82M Buy
130,196
+63,336
+95% +$724K ﹤0.01% 3218
2017
Q1 		$917K Buy
66,860
+6,758
+11% +$70.2K ﹤0.01% 3373
2016
Q4 		$431K Buy
60,102
+7,151
+14% +$78.4K ﹤0.01% 3568
2016
Q3 		$802K Buy
52,951
+2,736
+5% +$36K ﹤0.01% 3407
2016
Q2 		$495K Buy
+50,215
New +$689K ﹤0.01% 3521

Other funds holding SNDX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

Northern Trust's SNDX Position: Q1 2026 in Review

Northern Trust increased its Syndax Pharmaceuticals (SNDX) stake by 3.7% in Q1 2026, buying an estimated $582K and bringing the position to 755,719 shares worth $17.7M. The position accounts for ﹤0.01% of the portfolio, ranked #1751.

Northern Trust first reported a position in SNDX in Q2 2016 and has held it in 40 quarters since. The position peaked at $17.7M in Q1 2024. 246 funds tracked by Wall St. Rank hold SNDX as of Q1 2026.

  • Northern Trust held 755,719 shares of Syndax Pharmaceuticals worth $17.7M as of Q1 2026.
  • Northern Trust bought 26,798 Syndax Pharmaceuticals shares in Q1 2026, an estimated $582K.
  • Syndax Pharmaceuticals made up ﹤0.01% of Northern Trust's portfolio in Q1 2026, its #1751 holding.
  • Northern Trust first reported a position in Syndax Pharmaceuticals in Q2 2016 and has held it in 40 quarters since.
  • Northern Trust's Syndax Pharmaceuticals position peaked at $17.7M in Q1 2024.
  • 246 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q1 2026.

Based on Northern Trust's 13F filing for Q1 2026, filed 14 May 2026.